Mereo Biopharma Group PLC
NASDAQ:MREO
Mereo Biopharma Group PLC
NASDAQ:MREO
Price:
0.4073
USD
2.41%
Market Closed
Market Cap:
$64.8m
Relative Value
The Relative Value of one
MREO
stock under the Base Case scenario is
0.2389
USD.
Compared to the current market price of 0.4073 USD,
Mereo Biopharma Group PLC
is
Overvalued by 41%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MREO
Relative Value
Base Case
0.2389
USD
Overvaluation 41%
Multiples Across Competitors
MREO Competitors Multiples
Mereo Biopharma Group PLC Competitors
Mereo Biopharma Group PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
Mereo Biopharma Group PLC
NASDAQ:MREO
|
63.3m USD | 93.8 | -1.1 | 0 | 0 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
402.2B USD | 6.7 | 171.3 | 16.6 | 23.5 | |
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD | 462 374.5 | -2 631.9 | -2 389.6 | -2 389.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
206.8B USD | 5.6 | 26.9 | 15.3 | 15.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
182.9B USD | 6.2 | 21.5 | 14.6 | 14.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
122.6B USD | 10.2 | 31.1 | 23.8 | 24.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.3B USD | 5.8 | 18.5 | 14 | 15.9 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.3B EUR | 14.3 | 33.5 | 57.4 | 59 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.6B AUD | 3.2 | 16.6 | 11.4 | 14.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
